Physician profile

Sarah Barnes

Family · The Woodlands, TX

NPI 1548455132

$3,016.56

in general payments reported to CMS, 2019-2025

37 companies · $733 in 2025

The $733 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).

See the full distribution for Family

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,292.83
Education$8.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $426.22 2022-2025
Astrazeneca Pharmaceuticals LP $380.88 2022-2025 Farxiga, Airsupra, Breztri
Lilly USA, LLC $367.70 2022-2025 Jardiance, Mounjaro, Zepbound
Novo Nordisk INC $332.80 2023-2025 Wegovy, Ozempic, Rybelsus
Abbott Laboratories $221.71 2021-2023 Assurity
Jazz Pharmaceuticals INC. $123.12 2022
Pfizer INC. $119.43 2023-2025
Baxter Healthcare $99.78 2023-2024 Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor
Amarin Pharma, INC. $85.30 2022
Exact Sciences Corporation $85.17 2023-2025 Cologuard Collection Kit
Bayer Healthcare Pharmaceuticals INC. $66.52 2022-2023
Amgen INC. $59.45 2025 Repatha, Otezla
Sumitomo Pharma America, INC. $52.53 2023-2025 Gemtesa
Tolmar, INC. $51.64 2024-2025 Jatenzo
Janssen Pharmaceuticals, INC $38.70 2023-2025 Spravato, Xarelto
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Inspire Medical Systems, INC. $37.79 2025 Inspire
Otsuka America Pharmaceutical, INC. $35.52 2023-2024 Rexulti
Glaxosmithkline, LLC. $34.92 2023 Arexvy, Trelegy Ellipta
Seqirus USA INC $33.38 2025 Fluad, Flucelvax
Medtronic, INC. $30.12 2023-2025 Intellis Adaptivestim, Venaseal
Biohaven Pharmaceutical Holding Company LTD. $27.65 2022
Shield Therapeutics INC $27.57 2023 Accrufer
Dexcom, INC. $27.03 2025 Dexcom G6 Transmitter
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $24.74 2022
Daiichi Sankyo INC. $24.44 2022
Noven Therapeutics, LLC $20.95 2023 Xelstrym
Phathom Pharmaceuticals, INC. $19.05 2025 Voquezna
Boehringer Ingelheim Pharmaceuticals, INC. $17.96 2025 Jardiance
Dynavax Technologies Corporation $17.93 2023 Heplisav-B
Organon LLC $17.51 2023 Nexplanon
Astellas Pharma US INC $17.40 2024 Veozah
Sunovion Pharmaceuticals INC. $16.88 2022
Neos Therapeutics, LP $16.63 2024 Adzenys Xr-Odt
Allergan, INC. $15.14 2022
Idorsia Pharmaceuticals US INC $14.59 2023 Quviviq
Ibsa Pharma INC. $14.46 2025 Flector, Licart, Tirosint
Merck Sharp & Dohme LLC $13.95 2024 Gardasil, Gardasil 9, Capvaxive

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sarah Barnes

$3,016.56

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $733 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/11010999/sarah-barnes

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.